Matthew Pauls was appointed Director of Palvella Therapeutics, Inc. As of November 6, 2026, Palvella Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 13, 2026 to June 30, 2026, naming 2 appointments (Form 8-K, June 30, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Palvella Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Palvella Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-13 to 2026-06-30. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Palvella Therapeutics, Inc. files it.
Also on the record for Palvella Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 28, 2026 | Stake report, Schedule 13G/A, by Jennison Associates LLC | 7.7% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 4.7% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by First Light Asset Management, LLC | 5.34% of the class | 5%+ stakes | Source |
| August 10, 2026 | Stake report, Schedule 13G, by PRUDENTIAL FINANCIAL INC | 6.7% of the class | 5%+ stakes | Source |
| August 3, 2026 | Stake report, Schedule 13G, by Jennison Associates LLC | 6.7% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.7% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by First Light Asset Management, LLC | 7.49% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 7.1% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P. | 6% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 9.99% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by SUVRETTA CAPITAL MANAGEMENT, LLC | 7.4% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P. | 4.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Palvella Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Palvella Therapeutics, Inc. and the records around it.
Palvella Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- First Light Asset Management, LLC also filed stake reports on 12 other companies: NeuroPace Inc (Sep 2026), Neogenomics, Inc. (Aug 2026), TriSalus Life Sciences, Inc. (Jul 2026)
- Jennison Associates LLC also filed stake reports on 14 other companies: LENDINGTREE INC (Oct 2026), REZOLUTE INC (Oct 2026), NEUROGENE INC (Oct 2026)
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026)
Watch Palvella Therapeutics, Inc.
Get an email when Palvella Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Palvella Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Palvella Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Palvella Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-30 | In | Director | 8-K, 2026-06-30 | ||
| 2026-04-13 | In | Director | 8-K, 2026-04-13 |
Who leads Palvella Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Matthew Pauls, appointed (filed 2026-06-30).
New leaders reset buying decisions — get the Full Report on Palvella Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Palvella Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Palvella Therapeutics, Inc.Every change, in the filing's words
Appointed: Matthew Pauls, Director
On June 29, 2026 (the "Appointment Date"), the Board of Directors (the "Board") of Palvella Therapeutics, Inc. (the "Company") increased the size of the Board from seven to eight members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed Matthew Pauls, to serve as a Class I director, with an initial term expiring at the Company's 2027 Annual Meeting of Stockholders.
- Mr. Pauls, 56, currently serves as the Chief Executive Officer of Savara, Inc. (NASDAQ: SVRA) ("Savara"), a public clinical-stage biopharmaceutical company focused on rare respiratory diseases, a role he has held since December 2020.
- Prior to Savara, Mr. Pauls served as President and Chief Executive Officer of Strongbridge Biopharma plc ("Strongbridge"), a public biopharmaceutical company focused on rare respiratory diseases, which was acquired by Xeris Pharmaceuticals, Inc. At Strongbridge, he led the company through its Nasdaq initial public offering, oversaw the successful commercialization of KEVEYIS and Macrilen, and advanced RECORLEV through pivotal Phase 3 development for Cushing's syndrome.
- Earlier in his career, Mr. Pauls was Chief Commercial Officer of Insmed, Inc., where he led global commercial and technical operations, and held senior leadership roles at Shire Pharmaceuticals Group Plc, Bristol-Myers Squibb Company, and Johnson & Johnson Services, Inc. Mr. Pauls has served as a member of Savara's board of directors since April 2017 and as chair of Savara's board since September 2020.
Appointed: John Doux, Director
On April 13, 2026 (the " Appointment Date "), the Board of Directors (the " Board ") of Palvella Therapeutics, Inc. (the " Company ") increased the size of the Board from six to seven members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed John Doux, M.D., to serve as a Class III director, with an initial term expiring at the Company's 2026 Annual Meeting of Stockholders.
- Dr. Doux, 57, is a board-certified dermatologist and a fellow of the American Academy of Dermatology.
- Since 2004, he has served as an analyst at Palo Alto Investors LP, a physician-led healthcare focused investment firm, where he has been involved in investments in several leading publicly traded companies developing and commercializing novel therapies for serious, rare diseases.
- Dr. Doux co-founded the Dermatology Summit and the Dermatology Innovation Forum and served on the conference's board of directors from 2013 to 2021.
- Dr. Doux has served as a board trustee for the Pachyonychia Congenita Project, a public charity, since June 2025, and as a director on the board of directors of Kamari Pharma, a privately-held clinical stage biotechnology company, since April 2024.
- From 2019 to 2022, Dr. Doux served on the board of directors of Palvella Therapeutics, Inc. prior to its reverse merger with the Company.
- He has also previously served on the boards of multiple biotechnology companies, including Ceptaris Therapeutics, Inc., which developed VALCHLOR for cutaneous T-cell lymphoma and was acquired by Actelion.
- Dr. Doux maintained a clinical practice in medical and surgical dermatology from 1999 to 2016.
- Dr. Doux received his B.S. and M.D. from Stanford University and was a Howard Hughes Medical Institute Fellow in the laboratory of Dr. David Woodley.
Tools for this story
Each opens in a new tab, filled in for Palvella Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.